Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 30, 2010

Icon Sets Up Additional Lab Facility in China

  • Icon reports the opening of a laboratory facility in Tianjin, China, in partnership with Fountain Medical Development. It is Icon’s third lab in the Asia-Pacific region.

    Icon Central Laboratories China offers 3,000 square feet of laboratory space and is located 70 miles from Beijing. It will deliver site support services to clinical investigators throughout the country. The facility will offer a menu of testing services that includes chemistry, hematology, coagulation, and immunology.

    The laboratory received CAP (College of American Pathologists) accreditation in May and is also NGSP Level I Certified. Benefits include shorter shipping distances between clinical sites and existing laboratory testing facilities, Icon points out.

    Opening of the lab comes just a day after the NIAID signed on TRI and Icon in a Clinical Research Operations and Management Support contract with $19 million. The contract has a potential total value of up to $171 million over seven years.

    Icon has been operational in the Asia-Pacific region for over 10 years. The company says that it employs over 800 staff, with existing laboratory facilities situated in Bangalore and Singapore. Globally, Icon employs over 7,300 employees and operates from 71 locations in 39 countries.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »